The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant.
Open accessAbstract
Hepatitis B (HepB) vaccination is the primary means of preventing infections and complications caused by hepatitis B virus (HBV). On February 21, 2018, the Advisory Committee on Immunization Practices (ACIP) recommended Heplisav-B (HepB-CpG), a yeast-derived vaccine prepared with a novel adjuvant, administered as a 2-dose series (0, 1 month) for use in persons aged ≥18 years. The ACIP Hepatitis Vaccines Work Group conducted a systematic review of the evidence, including data from four randomized controlled trials assessing prevention of HBV infection and six randomized controlled trials assessing adverse events in adults. Seroprotective antibody to hepatitis B surface antigen (anti-HBs) levels were achieved in 90.0%-100.0% of subjects receiving HepB-CpG (Dynavax Technologies Corporation), compared with 70.5%-90.2% of subjects receiving Engerix-B (GlaxoSmithKline Biologicals). The benefits of protection with 2 doses administered over 1 month make HepB-CpG an important option for prevention of HBV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“High vaccination coverage rates with subsequent decreases in acute HBV infection incidence have been achieved among infants and adolescents (1318).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1318]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For each 1.1 million doses of vaccine administered, approximately one recipient will experience this type of reaction (1328); however, no deaths have been reported among these patients (1318,1328).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [1318]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schillie, S., Vellozzi, C., Reingold, A., Harris, A., Haber, P., Ward, J. W., & Nelson, N. P. (2018) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6701a1 · Cited by 815
Self-citationJackson, S., Lentino, J., Kopp, J., Murray, L., Ellison, W., Rhee, M., Shockey, G., Akella, L., Erby, K., Heyward, W. L., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2017.12.038 · Cited by 197
Halperin, S. A., Ward, B. J., Cooper, C., Predy, G., Díaz‐Mitoma, F., Dionne, M., Embreé, J., McGeer, A., Zickler, P., Moltz, K.-H., et al. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.01.087 · Cited by 135
Halperin, S. A., Dobson, S., McNeil, S., Langley, J. M., Smith, B. R., McCall-Sani, R., Levitt, D., Nest, G. V., Gennevois, D., & Eiden, J. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.095 · Cited by 134
Heyward, W. L., Kyle, M., Blumenau, J., Davis, M., Reisinger, K. S., Kabongo, M. L., Bennett, S. R., Janssen, R. S., Namini, H., & Martin, J. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.068 · Cited by 121
Janssen, R. S., Mangoo‐Karim, R., Pérgola, P. E., Girndt, M., Namini, H., Rahman, S., Bennett, S. R., Heyward, W. L., & Martin, J. T. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.05.067 · Cited by 81
Sablan, B. P., Kim, D. J., Barzaga, N. G., Chow, W. C., Cho, M., Ahn, S. H., Hwang, S. G., Lee, J.-H., Namini, H., & Heyward, W. L. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.02.001 · Cited by 68
Halperin, S. A., Ward, B. J., Dionne, M. S., Langley, J. M., McNeil, S., Smith, B. R., MacKinnon‐Cameron, D., Heyward, W. L., & Martin, J. T. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.24256 · Cited by 28
Cited by
Sorted by citations
Items 201–208 of 208
Singh, A. K., & Birda, C. L. (2026) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70687
Hepatitis B challenge dose in vaccinated healthcare personnel susceptible at hire
Hey, J. V., Ward, D., Buys, A., Caldera, F., & Hayney, M. S. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128589
Luan, N., Zhang, H., Lei, Z., Bi, R., Cao, H., Gao, D., He, Q., Zhang, X., Li, Q., & Liu, C. (2026) · Journal of Medical Virology · doi:10.1002/jmv.70971
Yang, J., Wang, F., & Huang, J. (2026) · Virology Journal · doi:10.1186/s12985-026-03188-0
Hepatitis B Vaccination in People Living with HIV: Bridging the Immunological Gap
Radi, C., Faraj, J. A., Idriss, J., Gromer, D. J., Saint-Victor, D. S., Eberhardt, C. S., Rouphael, N., & Kalash, S. (2026) · Vaccines · doi:10.3390/vaccines14070623
Shahim, E., Bahrololoom, R., Ataollahi, M., Jamalidoust, M., Hasani, A., Ilkhanipoor, H., Dashti, A. S., & Hamzavi, S. S. (2026) · Health Science Reports · doi:10.1002/hsr2.72700
Hepatitis B in Organ Transplantation—Current Evidence and Clinical Gaps
Fernández‐García, O. A., Hirsch, B. L., Abela, I. A., & Doucette, K. E. (2026) · Transplant Infectious Disease · doi:10.1111/tid.70299
Rodriguez-Chavez, I. R., Bujold, L. E., & Johnston, E. M. (2026) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2026.09.009
Metadata
- Authors
- Schillie, S., Harris, A., Link-Gelles, R., Romero, J., Ward, J., & Nelson, N.
- Affiliations
- Arkansas Children's Hospital (US)
- Corresponding author
- Schillie, Sarah
- Venue
- MMWR Morbidity and Mortality Weekly Report
- Published
- 2018-04-20
- Volume
- 67
- Issue
- 15
- Pages
- 455-458
- ISSN
- 0149-2195 (ISSN-L)
- 1545-861X
- PMC
- PMC6191098
- OpenAlex
- W2800687120
- Cited by
- 208
- References
- 9
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 19 · 2023: 21 · 2022: 25 · 2021: 37 · 2020: 42 · 2019: 25 · 2018: 8
- FWCI
- 21.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- MMWR Morbidity and Mortality Weekly Report (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services
- University of Arkansas
- University of Arkansas for Medical Sciences
- Centers for Disease Control and Prevention
- National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
- Topics
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- hepatitis B vaccine, CpG adjuvant, hepatitis B prevention, adult vaccination, seroprotection, anti-HBs antibodies, vaccine adverse events, Engerix-B, Advisory Committee on Immunization Practices recommendations
- MeSH terms
- Adjuvants, Immunologic, Adolescent, Adult, Centers for Disease Control and Prevention, U.S., Hepatitis B, Humans, Immunization Schedule, United States, Randomized Controlled Trials as Topic, Hepatitis B Vaccines, Practice Guidelines as Topic, Advisory Committees
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
